key: cord-0804113-bn0fegqg authors: Del Vecchio, C.; Brancaccio, G.; Brazzale, A. R.; Lavezzo, E.; Onelia, F.; Franchin, E.; Manuto, L.; Bianca, F.; Cianci, V.; Cattelan, A.; Toppo, S.; Crisanti, A. title: Emergence of N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests date: 2021-03-26 journal: nan DOI: 10.1101/2021.03.25.21253802 sha: e295d31c26f838168a263a24039728dbf3d3099a doc_id: 804113 cord_uid: bn0fegqg SARS-CoV-2 genetic variants are emerging as a major threat to vaccination efforts worldwide as they may increase virus transmission rate and/or confer the ability to escape vaccine induced immunity with knock on effects on the level of herd immunity and vaccine efficacy respectively. These variants concern the Spike protein, which is encoded by the S gene, involved in virus entry into host cells and the major target of vaccine development. We report here that genetic variants of the N gene can impair our ability to utilize antigenic tests for both diagnosis and mass testing efforts aimed at controlling virus transmission. While conducting a large validation study on the Abbott Panbio COVID-19 Ag test, we noticed that some swab samples failed to generate a positive result in spite of a high viral load in Rt-PCR assays. Sequencing analysis of viruses showing discordant results in the Rt-PCR and antigen assays revealed the presence of multiple disruptive amino-acid substitutions in the N antigen (the viral protein detected in the antigen test) clustered from position 229 to 374 a region known to contain an immunodominant epitope. A relevant fraction of the variants, undetected by the antigen test, contained the mutations A376T coupled to M241I. Intriguingly we found that virus sequences with this mutation were over-represented in the antigen-test-negative and PCR-positive samples and progressively increased in frequency over time in Veneto, a region of Italy that has aggressively scaled up the utilization of antigen tests, which reached nearly 68% of all the SARS-CoV-2 swab assays performed there. We speculate that mass utilization of antigen assays could create a selection pressure on the target that may favor the spread of undetectable virus variants. INTRODUCTION SARS-CoV-2 rapid antigen tests are immunoassays designed to identify in the nasopharyngeal or nasal swab the presence of a viral antigens thereby corroborating the diagnosis of the infection. Typically, these assays utilize immuno-chromatographic lateral flow design and high affinity monoclonal antibodies against an abundant protein that in the case of SARS-CoV-2 is the N antigen 1 . On August 26, 2020, the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for rapid antigen tests that can identify SARS-CoV-2, thereafter most countries followed suit 2 . The major advantage of antigen tests is their flexibility and ease of use. They can be performed in local settings with no convenient access to a molecular biology laboratory. They generate a result in about 15 minutes but require complex logistics when thousands of individuals are tested on the same occasion as they lack both automation and parallelism. The main limitation of SARS-CoV-2 antigen tests is sensitivity. These tests are less sensitive than real-time reverse transcription polymerase chain reaction (RT-PCR) and other nucleic amplification technology 3 . Preliminary results on the Liverpool pilot study with Innova lateral flow test (LFT) indicated that this assay had a sensitivity of 66% 4 and an even lower 49% 5 sensitivity was reported in other community testing in UK. A screening with the same test performed on the students at Birmingham University reported a worryingly low sensitivity of 3.2% amongst asymptomatic young individuals 4, 6 . It has been argued that this discrepancy was possibly due to the lower viral loads of Birmingham students compared with those examined at Liverpool. Rapid antigenic tests have been proposed as a flexible and powerful tool to implement effective surveillance regimens aimed at reducing virus prevalence in large target communities and to reduce transmission from asymptomatic individuals. It has been argued that if the test is repeated at least a couple of times on the same person at two-three days interval the sensitivity will increases because of the higher probability to intercept the peak of viral load in an infected individual 7 . Accordingly, a negative result on multiple occasions would indicate that the individual is a true negative or is in the declining phase of viral multiplication and therefore unlikely to be infectious. During October 2020 almost the entire adult population of Slovakia was tested using SARS-CoV-2 antigen assays 8 . In an unprecedented logistic effort 3.3 million individuals were tested in few days with a positivity rate of about 1% 8 . To minimize sensitivity problems the test was repeated a week later in regions with high prevalence. Unfortunately, no data is available on the overall sensitivity of the test utilized there under those epidemiological conditions. However, a few weeks after the testing was completed hospitalization plateaued suggesting that this effort may have helped to temporarily reduce transmission 8 . More recently massive population screenings with antigen tests have been carried out in different regions of the world including Italy 9,10 . Since the beginning of October, the Regione Veneto, one of the twenty-one administrative districts of Italy, has progressively scaled up the use of antigen tests in the effort to expand its testing and tracing capability. Out of 226,904 tests performed from the 15 th to the 22 th of February 2021, 153,020 were antigen swabs accounting for 67.4% of the total, the great majority of the them being manufactured by Abbott (Panbio™ COVID-19 Ag Rapid Test Device, ABBOTT Lake Country, IL, U.S.A.). Shortly after the introduction of this test as a screening tool for surveillance monitoring purposes country wide, we conducted a validation study to evaluate its overall performance and to assess its suitability to rapidly identify SARS-CoV-2 infections in patients admitted to hospital. We compared the performance of this test with RT-PCR on 1,441 patients examined at the A&E and the Infectious Diseases wards over a period of one month. We also systematically analysed the sequence of several viral samples that generated non concordant results in the antigen test and RT-PCR to discriminate between lack of sensitivity and the presence of virus variants undetectable to the antigen tests. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. The samples were collected from the 15th of September to the 16th of October 2020 from patients admitted to the A&E and Infectious disease wards of the University Hospital of Padua and from subjects who required SARS-CoV-2 testing for the following reasons: a) presence of symptoms indicating a possible SARS-CoV-2 infection (fever and/or cough and/or headache, diarrhea, asthenia, muscle pain, joint pain, loss of taste or smell, or shortness of breath, with or without pneumonia); and b) patients who were asymptomatic but had a contact with a confirmed case of SARS-CoV-2 infection during the previous ten days. All subjects were tested within one hour with both antigen Testing for SARS-CoV-2 with antigenic and molecular assays Two swabs were collected from each patient. One sample was processed with Panbio™ COVID- perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Sequence data and corresponding metadata, released from the 17th of February 2021, were downloaded from GISAID databank 16 and further analyzed to map the variants in N protein. Sequences with missing information and incomplete N protein were discarded. The analysis was conducted on the variants found in concordant (DNCOV+/ANCOV+) and discordant cases (DNCOV+/ANCOV-) (see Suppl. Mat. and GISAID acknowledgments where the list of accession numbers of considered sequences is available). The monthly prevalence trend of the variants found in concordant and discordant cases was plotted from January to December 2020 and reported for Europe, Italy, and the Veneto region ( Figure 7 ). P-values are evaluated at the 5% significance level; confidence intervals were computed with a confidence level of 95%. Continuous outcomes were compared using the two-sided Wilcoxon-Mann-Whitney test (two groups) and the Kruskall-Wallis test (> two groups) 17 . Pearson's chi-squared test statistic was used to compare proportions. The distribution of Ct values was estimated using a twocomponent Gaussian mixture. Logistic regression is used to model ANCOV test sensitivity against Ct level. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Table I) . We performed a logistic regression analysis to estimate the sensitivity of the antigen test at different levels of Ct values for both the S and ORF1 gene showing that the sensitivity of the test increases at progressively lowering Ct (Table II and In spite of a lower sensitivity, antigen tests could find a useful application to rapidly confirm the diagnosis of Covid-19 in symptomatic patients with respiratory symptoms showing at A&E thus All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in (Table IV) . However, this gradient is not statistically significant at the 5% significance level possibly due the small sample size of each group (28, 5 and 18 patients). The viral load is known to decrease with time 18 Q229H, R209I, and T141I appeared sporadically in Europe over the period examined but never increased in frequency. One conservative amino-acid substitution A220V found in different clades increased in frequency to 60% in both Europe and Italy. The mutations G204R and R203K appeared very early from the start of the epidemics reaching 80% frequency by the end of June and declined thereafter. The amino-acid substitution A376T coupled with M234I found in 38% of all DNCOV+/ANCOV-virus sequences analysed appeared in both Europe and Italy at the beginning of July and after a modest rise this variant decreased to less than 5% by the end of December 2020. On the contrary in the Veneto region, where antigen tests have been massively used starting from the beginning of June, the frequency of this variant progressively increased to reach 20% of all sequences analysed during the same period. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.25.21253802 doi: medRxiv preprint carrying respectively mutations R209I, P365S, M234I-A376T, and D348Y failed to generate a positive signal thus suggesting that these assays use antibodies with similar specificities. The fact that some virus variants are "undetectable" irrespectively of the Ct value combined with a lower sensitivity of antigen tests may have accounted for the partial and disappointing results obtained when antigen tests were utilised in large population screens. It should also be considered perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.25.21253802 doi: medRxiv preprint Figure 7 : Monthly prevalence (percentage over total sequences) of N variants generating discordant DNCOV+ / ANCOV-(left panels) and concordant DNCOV+ / ANCOV+ (right panels) result in molecular and antigen swab. Shaded areas show the 95% confidence bands for each different region. No sequence data are available for Veneto region in the months of January, February, July, and September. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table I : Overall sensitivity/specificity and PPV/NPV for ANCOV test. 1 1 The estimates of sensitivity slightly differ from the ones reported in Table II , as the latter obtains the estimates of sensitivity from the fitted logistic regression model. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Table II : Sensitivity estimates of ANCOV test at increasing Ct value for the S and ORF1 gene generated by a logistic regression model, with 95% confidence intervals. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations Update: FDA Authorizes First Diagnostic Test Where Results Can Be Read Directly From Testing Card Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19 Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show Covid-19: Tests on students are highly inaccurate, early findings show Rethinking Covid-19 Test Sensitivity -A Strategy for Containment The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia German-speaking Italian province conducts mass rapid test Austria bets on millions of tests to contain COVID-19 -URL Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes Trimmomatic: a flexible trimmer for Illumina sequence data Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM The Sequence Alignment/Map format and SAMtools VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing disease and diplomacy: GISAID's innovative contribution to global health. Global challenges A guide to modern statistical analysis of immunological data Temporal dynamics in viral shedding and transmissibility of COVID-19 COVID-19 Ag Rapid Test Device (Nasopharyngeal) IFU for Comprehensive antibody epitope mapping of the nucleocapsid protein of ACKNOWLEDGEMENTS COVID-19 emergency fund from University of Padova (grant number: TOPP_PRIV20_01) to ST.We gratefully acknowledge the Authors from the Originating Laboratories and the Submitting Laboratories who generated and shared via GISAID the data on which this research is based. The authors declare no competing interests.